ASLN Aslan Pharmaceuticals
- 0.4410
- -0.0190-4.13%
Aslan Pharmaceuticals News
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading
Asian equities traded in the US as American depositary receipts were treading water Wednesday morning, as they nudged 0.065% lower to 1,841.39 on the S&P Asia 50 ADR Index. From North Asia, the gainer
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
ASLAN management will present new data from the interim analysis of the TREK-DX studyRegister here to attend the webinar event on May 7, 2024 at 8:00 AM ET SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note in Monday Trading
Asian equities traded in the US as American depositary receipts kicked off the week relatively flat Monday morning, nudging 0.037% higher to 1,855.14 on the S&P Asia 50 ADR Index. From North Asia, the
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.5%
Asian equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.6% to 1,850.73 on the S&P Asia 50 ADR Index, which is poised to end the week around 3.5% h
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
Tech stocks were leading Asian equities traded in the US as American depositary receipts lower Thursday morning, falling 0.83% to 1,827.37 on the S&P Asia 50 ADR Index. From North Asia, the gainers we
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to
HC Wainwright & Co. : The ASLAN Pharma (ASLN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
HC Wainwright & Co. : The ASLAN Pharma (ASLN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher
Asian equities traded in the US as American depositary receipts kicked off the week on a positive note, rising 0.88% to 1,799.39 on the S&P Asia 50 ADR Index in Monday trading. From North Asia, the ga
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo.
Aslan Pharmaceuticals Reports Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-Experienced Atopic Dermatitis Patients
https://www.sec.gov/Archives/edgar/data/1722926/000095017024046201/asln-ex99_1.htm
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
ASLAN Pharmaceuticals (Nasdaq: ASLN) today announced that it received a letter (the "Letter") on April 18, 2024 from The Nasdaq Stock Market ("Nasdaq") informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company's stockholders' equity be at least $2.5 million (the "Stockholders' Equity Requirement").
Asian Equities Traded in the US as American Depositary Receipts Fall Again in Friday Trading
Asian equities traded in the US as American depositary receipts were trending lower Friday morning, declining 0.69% to 1,786.62 on the S&P Asia 50 ADR Index. The index is poised to close out the week
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading
After opening the trading session in positive territory, Asian equities traded in the US as American depositary receipts fell flat Wednesday morning, declining 0.061% to 1,823.73 on the S&P Asia 50 AD
Financial, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
Financial and telecoms stocks led Asian equities traded in the US as American depositary receipts sharply lower Tuesday morning, falling 1.33% to 1,822.99 on the S&P Asia 50 ADR Index. From North Asia
HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $9 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma with a Buy and maintains $9 price target.
ASLAN Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 1646.89% HC Wainwright & Co. → $9 Reiterates Buy → Buy 03/18/2024 1646.89% HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Rewalk Robotics (LFWD) and Apellis Pharmaceuticals (APLS)
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
Asian equities traded in the US as American depositary receipts were sharply lower, falling 1.89% to 1,877.95 Friday morning on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by fint
Aslan Pharmaceuticals Launches $12M ADS Offering
Analysis
Price Target
No Data
